grant

Identifying drug targets in M. abscessus through the application of fluorescent probes

Organization OREGON HEALTH & SCIENCE UNIVERSITYLocation PORTLAND, UNITED STATESPosted 9 Feb 2026Deadline 31 Jan 2028
NIHUS FederalResearch GrantFY2026AccelerationAcuteAffectAnabolismAntibiotic AgentsAntibiotic DrugsAntibioticsAssayB subtilisB. subtilisBacillus subtilisBacteriaBacterial InfectionsBioassayBiological AssayBiologyBronchiectasisCase StudyCase-Base StudiesCell WallChemicalsChronicClinicalClinical ManagementClinical Trials DesignComplementComplement ProteinsCy5Cystic FibrosisDataDeath RateDevelopmentDiseaseDisorderDrug TargetingDrug resistanceDrugsE coliE. coliEducational process of instructingEnsureEnzyme GeneEnzyme InhibitionEnzymesEscherichia coliFDA licensed drugsFDA-approved agentsFDA-approved drugFDA-approved medicationsFDA-approved pharmaceuticalsFDA-approved therapeutic agentFluorescent ProbesFood and Drug Administration approved drugFood and Drug Administration approved medicationsFood and Drug Administration approved pharmaceuticalsG24 proteinGelGenus MycobacteriumGoalsGuidelinesInfectionKnowledgeLabelLeadLeftLogicLungLung DiseasesLung Respiratory SystemLung infectionsM abscessusM aviumM tbM tuberculosisM. abscessusM. aviumM. tbM. tuberculosisMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMedicationMiceMice MammalsMiscellaneous AntibioticMucoviscidosisMurineMusMycobacterial InfectionMycobacteriumMycobacterium InfectionsMycobacterium abscessusMycobacterium aviumMycobacterium tuberculosisMycobacteroides abscessusNIAIDNational Institute of Allergy and Infectious DiseasePatientsPatternPb elementPenicillin-Binding ProteinsPeptidyl TransferasesPeptidyl TranslocasesPeptidyltransferasePersonsPharmaceutical PreparationsPredispositionProteinsProteomicsPulmonary DiseasesPulmonary DisorderRegimenRegulationResearchResistanceSchemeSurvey InstrumentSurveysSusceptibilityTeachingTestingTranspeptidasesTreatment ProtocolsTreatment RegimenTreatment ScheduleUnited StatesUpdateWorkbacteria infectionbacteria pathogenbacterial diseasebacterial pathogenbeta lactam antibioticbeta lactam hydrolasebeta-Lactamasebeta-Lactamhydrolasebeta-Lactamsbiosynthesiscase reportclinical relevanceclinically relevantcomplementationcrosslinkcyanine dye 5designdesigningdevelopmentaldisease of the lungdisorder of the lungdrug resistantdrug/agentheavy metal Pbheavy metal leadimprovedinnovateinnovationinnovativeinsightlung disordermedical countermeasuremodel organismmortality ratemouse modelmtbmurine modelmycobacterialnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynon-tuberculosis mycobacterianon-tuberculosis mycobacterialnon-tuberculous mycobacterianon-tuberculous mycobacterialnontuberculosis mycobacterialnontuberculous mycobacterianontuberculous mycobacterialnovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachpathogenpathogenic bacteriapulmonarypulmonary infectionsresistance to Drugresistantresistant to Drugresponsesynergismtherapeutically effectiveβ lactam antibioticβ-Lactamaseβ-Lactams
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Project Summary
In the United States, a person is more likely to be infected by a non-tuberculous mycobacteria (NTM) than

Mycobacterium tuberculosis (Mtb). Most NTM pulmonary infections are caused by one of two species:

Mycobacterium avium or Mycobacterium abscessus (Mab). Of the two, infections with Mab are the most

difficult to cure and,…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →
Identifying drug targets in M. abscessus through the application of fluorescent probes — OREGON HEALTH & SCIENCE UNIVERS | Dev Procure